What phase of clinical trials is Kangpe's CBL-514 currently in?

CBL-514 is currently in phase 3 clinical trials, with the SUPREME-02 (CBL-0302) trial filing submitted to the Australian HREC.

How many subjects are expected for this clinical trial?

The phase 3 clinical trial SUPREME-02 is expected to enroll approximately 320 subjects across the US, Canada, and Australia.

Why is this new drug being developed?

Most current fat reduction treatments are invasive surgeries with side effects; existing non-surgical products suffer from poor efficacy and risks, leaving a large unmet market need.

AI News NQ Analysis

[Kangpe] CBL-514 Injection Files for the Second Multi-national Pivotal Phase 3 Clinical Trial (CBL-0302) with Australian HREC

NQ Score 0/100

N1 Content Completeness 5

AI Summary (NQ-processed)

Kangpe Biotechnology announced on May 20, 2026, that it has completed the clinical trial application to the Australian HREC for its second multi-national pivotal phase 3 clinical trial (SUPREME-02/CBL-0302) of CBL-514 injection for reducing abdominal subcutaneous fat.

AI Analysis

Frequently Asked Questions

Q: What phase of clinical trials is Kangpe's CBL-514 currently in?: A: CBL-514 is currently in phase 3 clinical trials, with the SUPREME-02 (CBL-0302) trial filing submitted to the Australian HREC.
Q: How many subjects are expected for this clinical trial?: A: The phase 3 clinical trial SUPREME-02 is expected to enroll approximately 320 subjects across the US, Canada, and Australia.
Q: Why is this new drug being developed?: A: Most current fat reduction treatments are invasive surgeries with side effects; existing non-surgical products suffer from poor efficacy and risks, leaving a large unmet market need.